Trevi Therapeutics, Inc.
TRVI$1.45B
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaNEW HAVEN34 employees
Drugs in Pipeline
5
Phase 3 Programs
4
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
TRVI News
Catalyst Timeline
0 upcoming, 1 past
No catalysts found.
Drug Pipeline
Nalbuphine ER Tablets
Prurigo Nodularis
nalbuphine HCl ER tablets 90 mg BID
Prurigo Nodularis
nalbuphine HCl ER tablets 60 mg BID
Uremic Pruritus
nalbuphine HCl ER
Uremic Pruritus
NAL ER
Refractory Chronic Cough
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Nalbuphine ER Tablets | Phase 3 | Prurigo Nodularis | - | - |
nalbuphine HCl ER tablets 90 mg BID | Phase 3 | Prurigo Nodularis | - | - |
nalbuphine HCl ER tablets 60 mg BID | Phase 3 | Uremic Pruritus | - | - |
nalbuphine HCl ER | Phase 3 | Uremic Pruritus | - | - |
NAL ER | Phase 2 | Refractory Chronic Cough | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply